CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Emotion- and Relationship-Focused Therapeutic InterviewWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D059352 Musculoskeletal Pain NIH 0.45

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Emotion- and Relationship-Focused Therapeutic Interview for Chronic Musculoskeletal Pain: A Randomized Trial

The goal of the study is to determine whether a brief, therapeutic interview can help patients improve their pain and health by addressing psychological issues that are known to drive chronic musculoskeletal pain. This randomized, controlled trial tests the efficacy of a brief, one-session therapeutic interview for patients with chronic musculoskeletal pain and histories of childhood adversity. Adults with chronic musculoskeletal pain will be randomized to either a therapeutic interview condition or a waitlist control condition. The therapeutic interview will be 90-minute session during which participants will be encouraged to disclose stressful experiences, express important emotions, and identify connections between their life stress and their pain, which we hope will increase their psychological attributions for pain and reduce their pain, interpersonal problems, and psychological distress. The study will compare the therapeutic interview condition to a delayed interview condition and will follow patients for 5 weeks to identify changes in response to the interview. Participants in the therapeutic interview condition are expected to show more improvement on pain severity, pain interference, psychological distress, interpersonal function, and psychological attitudes toward pain at follow-up, relative to participants in the delayed interview condition.

NCT04498663 Musculoskeletal Pain Behavioral: Emotion- and Relationship-Focused Therapeutic Interview
MeSH:Musculoskeletal Pain

Primary Outcomes

Description: Brief Pain Inventory pain severity scale (0 - 10; higher values = greater pain severity)

Measure: Change in pain severity from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Brief Pain Inventory pain interference scale (0 - 10; higher values = greater pain interference)

Measure: Change in pain interference from baseline to 5-week follow-up

Time: 5-week follow-up

Description: PROMIS anxiety scale (0 to 4; higher values = greater anxiety)

Measure: Change in anxiety from baseline to 5-week follow-up

Time: 5-week follow-up

Description: PROMIS depression scale (0 to 4; higher values = greater depression)

Measure: Change in depression from baseline to 5-week follow-up

Time: 5-week follow-up

Description: PROMIS anger scale (0 to 4; higher values = greater anger)

Measure: Change in anger from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Rathus Assertiveness Schedule short form (- 3 to + 3; higher values = greater assertion)

Measure: Change in assertiveness from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Affect Phobia Test (1 to 5; lower values = affect phobia)

Measure: Change in affect phobia from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Pain attributions psychological subscale (0 to 4; higher values = greater psychological attribution)

Measure: Change in pain attributions to psychological processes from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Pain attributions brain subscale (0 to 4; higher values = greater brain attributions)

Measure: Change in pain attributions to brain processes from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Alcohol use item (1 to 7; higher = greater alcohol use)

Measure: Change in alcohol use frequency from baseline to 5-week follow-up

Time: 5-week follow-up

Description: Item assessing pain medication use (1 to 5; higher = greater medication use)

Measure: Change in pain medication use from baseline to 5-week follow-up

Time: 5-week follow-up


No related HPO nodes (Using clinical trials)